Anti-PEG immunity: emergence, characteristics, and unaddressed questions.
about
Optimizing ultrasound molecular imaging of secreted frizzled related protein 2 expression in angiosarcoma.mRNA vaccine delivery using lipid nanoparticles.Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuriaPEGylation as a strategy for improving nanoparticle-based drug and gene deliveryTranslation and Clinical Development of Antithrombotic Aptamers.Nanomedicines for renal disease: current status and future applicationsSurface functionalization of polymeric nanoparticles for tumor drug delivery: approaches and challenges.Systems-level thinking for nanoparticle-mediated therapeutic delivery to neurological diseases.The Mucus Barrier to Inhaled Gene Therapy.Cell membrane-derived nanomaterials for biomedical applications.Biomimetic and bioinspired nanoparticles for targeted drug delivery.Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir.Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucusEngineered Nanomedicine with Alendronic Acid Corona Improves Targeting to Osteosarcoma.Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation.An Albumin-Oligonucleotide Assembly for Potential Combinatorial Drug Delivery and Half-Life Extension Applications.Co-coating of receptor-targeted drug nanocarriers with anti-phagocytic moieties enhances specific tissue uptake versus non-specific phagocytic clearance.Sensitive and Quantitative Detection of Anti-Poly(ethylene glycol) (PEG) Antibodies by Methoxy-PEG-Coated Surface Plasmon Resonance Sensors.Brain-Penetrating Nanoparticles for Analysis of the Brain Microenvironment.Contribution of Kupffer cells to liposome accumulation in the liver.Physician Awareness of Immune Responses to Polyethylene Glycol-Drug Conjugates.Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer.Cell Membrane Coating Nanotechnology.Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action.Polymer Therapeutics: Biomarkers and New Approaches for Personalized Cancer Treatment.The Multifaceted Uses and Therapeutic Advantages of Nanoparticles for Atherosclerosis Research.Anticancer nanoparticulate polymer-drug conjugate.RNA interference: new mechanistic and biochemical insights with application in oral cancer therapy.Main trends of immune effects triggered by nanomedicines in preclinical studies
P2860
Q30359354-99D4F1DB-A473-4F20-A737-DE822BA0D3E9Q33711685-E5030E2F-8120-491B-9E7B-6A56EBCD7A68Q33902253-DB1F04AE-C412-4327-BDCD-63945E0442F9Q36304253-8FB69AD5-171F-4052-9D00-2ED5BD6D9022Q36703361-5D9993E7-1756-4B4F-8050-9A0235B857CCQ36987361-7DE0B2E2-9783-4259-8CC9-F4BFD991689AQ38802375-D01F83ED-9D9E-45CC-AA5B-E4E8510A0866Q38899902-F9FE34F5-74BA-41C0-A972-875038EEA670Q38937398-84426877-1D94-49B6-B092-F537E10F7F55Q38959100-98B8D3A3-9474-496E-A867-CA5E6DF5CD11Q39178313-BCECCA90-48F9-44AF-B828-CA975696E7E7Q39210548-E00B6081-5269-453C-BDA6-560F7B8E3DDFQ40075268-908EFA65-23A3-40D1-B3DA-084BC17C3B97Q40647901-FE61AC28-E450-4936-9C42-52E7BD1BB31EQ42241790-00F63360-8194-4944-AB7D-0937188290E0Q45873829-FA5FCC8D-667E-404B-9993-CCE60614DF66Q47102857-07B246EF-9F31-42AC-8C21-F7558466A682Q47288556-B6D26414-8224-47AA-868D-95FFC92C4B7BQ47782730-F32D2776-5951-4A8A-AA6D-72324AA00249Q47902077-EC8E8589-0041-4152-8F16-2B0B07D15D2BQ48291956-DB41E061-20DA-43D1-AF85-CC4EE4881083Q48718420-7A75AACF-B6C5-45EB-B285-E4A6076120AEQ49565303-A27D6553-A939-4AAF-B906-E14D40E411A9Q50285020-4BC3CD60-C87F-4054-8ABF-0C93D4A0EFCDQ52628718-F3F054BB-03C1-4C3D-847B-C2160D727DD7Q52649955-B69E79C8-EABA-4901-A6FB-0E659853F6FDQ52707854-46CEC9D1-C2A2-4250-A713-24D5C45AEFA2Q54402965-DEB96385-4D5C-4E42-A7B3-D02F1D8ECFADQ55030497-72959287-6D68-43E2-BEFA-9F7E8E27459DQ55360697-37F1ACF5-EC55-4F78-B3F5-6EDC0FEC1AC7Q57074417-857EDC33-D84D-4430-B498-CE33152525E1
P2860
Anti-PEG immunity: emergence, characteristics, and unaddressed questions.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Anti-PEG immunity: emergence, characteristics, and unaddressed questions
@nl
Anti-PEG immunity: emergence, characteristics, and unaddressed questions.
@ast
Anti-PEG immunity: emergence, characteristics, and unaddressed questions.
@en
type
label
Anti-PEG immunity: emergence, characteristics, and unaddressed questions
@nl
Anti-PEG immunity: emergence, characteristics, and unaddressed questions.
@ast
Anti-PEG immunity: emergence, characteristics, and unaddressed questions.
@en
prefLabel
Anti-PEG immunity: emergence, characteristics, and unaddressed questions
@nl
Anti-PEG immunity: emergence, characteristics, and unaddressed questions.
@ast
Anti-PEG immunity: emergence, characteristics, and unaddressed questions.
@en
P2860
P3181
P356
P1476
Anti-PEG immunity: emergence, characteristics, and unaddressed questions.
@en
P2093
P2860
P304
P3181
P356
10.1002/WNAN.1339
P407
P577
2015-02-23T00:00:00Z